Pioglitazone

Generic Name
Pioglitazone
Brand Names
Actoplus Met, Actos, Duetact, Incresync, Oseni, Tandemact, Pioglitazone Accord, Pioglitazone Actavis
Drug Type
Small Molecule
Chemical Formula
C19H20N2O3S
CAS Number
111025-46-8
Unique Ingredient Identifier
X4OV71U42S
Background

Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus. It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert in vivo with little consequence. The thiazolidinedione class of medications, which also includes rosiglitazone and troglitazone, exerts its pharmacological effect primarily by promoting insulin sensitivity and the improved uptake of blood glucose via agonism at the peroxisome proliferator-activated receptor-gamma (PPARγ). PPARs are ligand-activated transcription factors that are involved in the expression of more than 100 genes and affect numerous metabolic processes, most notably lipid and glucose homeostasis.

Thiazolidinediones, including pioglitazone, have fallen out of favor in recent years due to the presence of multiple adverse effects and warnings regarding their use (e.g. congestive heart failure, bladder cancer) and the availability of safer and more effective alternatives for patients with type 2 diabetes mellitus.

Indication

Pioglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is also available in combination with metformin, glimepiride, or alogliptin for the same indication.

Associated Conditions
Diabetes, Diabetic Neuropathies, Type 2 Diabetes Mellitus
Associated Therapies
-

Triple Therapy in Type 2 Diabetic Patients

First Posted Date
2013-07-10
Last Posted Date
2013-07-10
Lead Sponsor
University of Pavia
Target Recruit Count
64
Registration Number
NCT01895569
Locations
🇮🇹

IRCCS Policlinico S. Matteo Foundation, Pavia, Italy

Safety and Efficacy Study to Compare Vildagliptin to Pioglitazone as Adding on Metformin in Type 2 Diabetes

Phase 4
Completed
Conditions
Interventions
First Posted Date
2013-06-21
Last Posted Date
2019-03-21
Lead Sponsor
Pusan National University Hospital
Target Recruit Count
287
Registration Number
NCT01882907
Locations
🇰🇷

Dong-AUniversity Medical Center, Busan, Korea, Republic of

🇰🇷

Changwon Fatima Hospital, Changwon, Korea, Republic of

🇰🇷

Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of

and more 12 locations

A Phase II Study of Pioglitazone for Patients With Cancer of the Pancreas

Phase 2
Completed
Conditions
Interventions
First Posted Date
2013-04-24
Last Posted Date
2021-03-01
Lead Sponsor
University of Texas Southwestern Medical Center
Target Recruit Count
14
Registration Number
NCT01838317
Locations
🇺🇸

UT Southwestern Medical Center, Dallas, Texas, United States

Mediators of Abnormal Reproductive Function in Obesity (MARO)

First Posted Date
2013-03-25
Last Posted Date
2015-03-17
Lead Sponsor
University of Colorado, Denver
Target Recruit Count
10
Registration Number
NCT01817400
Locations
🇺🇸

University of Colorado Denver Anschutz Medical Campus, Aurora, Colorado, United States

The Impact of Actos Treatment of Diabetes on Glucose Transporters in Muscle

Phase 4
Completed
Conditions
Interventions
First Posted Date
2013-02-27
Last Posted Date
2013-02-27
Lead Sponsor
East Tennessee State University
Target Recruit Count
12
Registration Number
NCT01799850
Locations
🇺🇸

ETSU Quillen College of Medicine, Johnson City, Tennessee, United States

Cellular Dynamics of Subcutaneous Fat Distribution in Obese Women

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2012-12-13
Last Posted Date
2021-04-30
Lead Sponsor
Pennington Biomedical Research Center
Target Recruit Count
63
Registration Number
NCT01748994
Locations
🇺🇸

Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States

Pioglitazone for the Treatment of Bipolar Depression

First Posted Date
2012-10-30
Last Posted Date
2017-01-27
Lead Sponsor
University Hospitals Cleveland Medical Center
Target Recruit Count
37
Registration Number
NCT01717040
Locations
🇺🇸

University Hospitals Cleveland Medical Center - Mood Disorders Program, Cleveland, Ohio, United States

Safety and Efficacy of Roflumilast and Pioglitazone in Treating Adults With Nonalcoholic SteatoHepatitis

First Posted Date
2012-10-10
Last Posted Date
2017-02-01
Lead Sponsor
AstraZeneca
Target Recruit Count
20
Registration Number
NCT01703260

Assessing the Impact of Pioglitazone on Skin Barrier Function in Atopic Dermatitis Patients

Not Applicable
Withdrawn
Conditions
Interventions
First Posted Date
2012-09-28
Last Posted Date
2014-12-02
Lead Sponsor
University of Rochester
Registration Number
NCT01695707
Locations
🇺🇸

University of Rochester Medical Center, Rochester, New York, United States

Pioglitazone in Thyroid Cancers

First Posted Date
2012-08-02
Last Posted Date
2017-10-26
Lead Sponsor
University of Michigan
Target Recruit Count
1
Registration Number
NCT01655719
Locations
🇺🇸

University of Pennsylvania, Philadelphia, Pennsylvania, United States

🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

🇺🇸

University of Michigan, Ann Arbor, Michigan, United States

and more 1 locations
© Copyright 2024. All Rights Reserved by MedPath